The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
Objectives. The persistence of silodosin and the reasons for withdrawal from treatment of previously untreated Japanese patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) were evaluated in real-life clinical practice. Methods. A total of 81 previously un...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2017-01-01
|
Series: | Advances in Urology |
Online Access: | http://dx.doi.org/10.1155/2017/4842025 |
id |
doaj-7e9a2549d5cc4bceac0bd53c81d623a9 |
---|---|
record_format |
Article |
spelling |
doaj-7e9a2549d5cc4bceac0bd53c81d623a92020-11-24T23:53:17ZengHindawi LimitedAdvances in Urology1687-63691687-63772017-01-01201710.1155/2017/48420254842025The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic HyperplasiaYoshinori Tanaka0Yasushi Tanuma1Naoya Masumori2Division of Urology, Hokkaido Prefectural Esashi Hospital, Esashi, JapanDivision of Urology, Hokkaido Social Welfare Association Hakodate Hospital, Hakodate, JapanDepartment of Urology, Sapporo Medical University School of Medicine, Sapporo, JapanObjectives. The persistence of silodosin and the reasons for withdrawal from treatment of previously untreated Japanese patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) were evaluated in real-life clinical practice. Methods. A total of 81 previously untreated Japanese patients diagnosed with LUTS/BPH were treated with silodosin monotherapy and prospectively followed for 4 years. The persistence rate was estimated using the Kaplan-Meier method. If silodosin had to be terminated or a patient did not come to the hospital, the reason was determined. Results. The 6-month, 1-year, 2-year, 3-year, and 4-year persistence rates were 63.0%, 56.8%, 50.6%, 44.4%, and 35.8%, respectively. The most frequent reason (22.2%) for withdrawal was symptom resolution. After silodosin treatment, the international prostate symptom score and the quality of life index were significantly improved and maintained for 4 years. Conclusions. 35.8% of previously untreated Japanese patients continued silodosin for 4 years. Many patients terminated silodosin for various reasons, the most frequent of which was symptom resolution. The effects of silodosin were maintained when the patients continued treatment. Trial Registration. This study was approved by the institutional review board of Hokkaido Prefectural Esashi Hospital (number 2007-2) and was registered in a public trial registry (UMIN000026910).http://dx.doi.org/10.1155/2017/4842025 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yoshinori Tanaka Yasushi Tanuma Naoya Masumori |
spellingShingle |
Yoshinori Tanaka Yasushi Tanuma Naoya Masumori The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia Advances in Urology |
author_facet |
Yoshinori Tanaka Yasushi Tanuma Naoya Masumori |
author_sort |
Yoshinori Tanaka |
title |
The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia |
title_short |
The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia |
title_full |
The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia |
title_fullStr |
The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia |
title_full_unstemmed |
The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia |
title_sort |
persistence of silodosin monotherapy and the reasons for withdrawal from treatment of previously untreated japanese patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia |
publisher |
Hindawi Limited |
series |
Advances in Urology |
issn |
1687-6369 1687-6377 |
publishDate |
2017-01-01 |
description |
Objectives. The persistence of silodosin and the reasons for withdrawal from treatment of previously untreated Japanese patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) were evaluated in real-life clinical practice. Methods. A total of 81 previously untreated Japanese patients diagnosed with LUTS/BPH were treated with silodosin monotherapy and prospectively followed for 4 years. The persistence rate was estimated using the Kaplan-Meier method. If silodosin had to be terminated or a patient did not come to the hospital, the reason was determined. Results. The 6-month, 1-year, 2-year, 3-year, and 4-year persistence rates were 63.0%, 56.8%, 50.6%, 44.4%, and 35.8%, respectively. The most frequent reason (22.2%) for withdrawal was symptom resolution. After silodosin treatment, the international prostate symptom score and the quality of life index were significantly improved and maintained for 4 years. Conclusions. 35.8% of previously untreated Japanese patients continued silodosin for 4 years. Many patients terminated silodosin for various reasons, the most frequent of which was symptom resolution. The effects of silodosin were maintained when the patients continued treatment. Trial Registration. This study was approved by the institutional review board of Hokkaido Prefectural Esashi Hospital (number 2007-2) and was registered in a public trial registry (UMIN000026910). |
url |
http://dx.doi.org/10.1155/2017/4842025 |
work_keys_str_mv |
AT yoshinoritanaka thepersistenceofsilodosinmonotherapyandthereasonsforwithdrawalfromtreatmentofpreviouslyuntreatedjapanesepatientswithlowerurinarytractsymptomssuggestiveofbenignprostatichyperplasia AT yasushitanuma thepersistenceofsilodosinmonotherapyandthereasonsforwithdrawalfromtreatmentofpreviouslyuntreatedjapanesepatientswithlowerurinarytractsymptomssuggestiveofbenignprostatichyperplasia AT naoyamasumori thepersistenceofsilodosinmonotherapyandthereasonsforwithdrawalfromtreatmentofpreviouslyuntreatedjapanesepatientswithlowerurinarytractsymptomssuggestiveofbenignprostatichyperplasia AT yoshinoritanaka persistenceofsilodosinmonotherapyandthereasonsforwithdrawalfromtreatmentofpreviouslyuntreatedjapanesepatientswithlowerurinarytractsymptomssuggestiveofbenignprostatichyperplasia AT yasushitanuma persistenceofsilodosinmonotherapyandthereasonsforwithdrawalfromtreatmentofpreviouslyuntreatedjapanesepatientswithlowerurinarytractsymptomssuggestiveofbenignprostatichyperplasia AT naoyamasumori persistenceofsilodosinmonotherapyandthereasonsforwithdrawalfromtreatmentofpreviouslyuntreatedjapanesepatientswithlowerurinarytractsymptomssuggestiveofbenignprostatichyperplasia |
_version_ |
1725470591955238912 |